HeartSciences Inc. (HSCS) · Nov 19, 2026 · Share issuance

HeartSciences financing opens dilution before Fortitude merger vote

$3.08M ATM capacity — Current prospectus limit: $3,077,649

HeartSciences’ new financing agreement offers a $50M ATM headline, but Form S-3 limits current sales to $3.08M as the Fortitude merger nears.

HeartSciences is a cash-starved cardiac-diagnostics company attempting to transform into the public vehicle for Fortitude’s Zcash-focused mining platform; its July 31, 2026 10-Q showed only $29,906 of cash and cash equivalents, while the merger still required shareholder approval.

The filing creates a financing channel, but not $50 million of immediate funding. HeartSciences signed an equity distribution agreement allowing sales of up to $50 million of common stock. However, the current Form S-3 shareholder-float limitation caps the prospectus supplement at only $3,077,649. 〔0〕

Key termFiling figureComparison
ATM authorization (EDA)$50.0M—
Current S-3 sale limit$3.077649M$50.0M authorization
Sales commission2.5%2.0% thereafter
Legal-fee reimbursement$15,000 + $5,000/bringdown—

This is a necessary liquidity option, but it brings dilution without guaranteed proceeds. Maxim is acting as an agent and is not required to buy the shares itself, so the agreement does not ensure that HeartSciences raises the available amount. 〔1〕 For a company with minimal cash and a merger-dependent business plan, the facility improves near-term funding flexibility, but the immediate capacity is small and any sales would dilute existing holders.

The financing also reinforces that the Fortitude transaction remains unfinished. The merger was already publicly announced and the definitive proxy statement had been filed, with the shareholder meeting scheduled for November 19, 2026; this 8-K does not advance closing terms or confirm completion.

Bottom line: This is a modestly negative financing update: HeartSciences gains a needed cash-raising mechanism, but the usable amount is only about $3.08 million and comes with potential dilution while the Fortitude merger is still pending.

What to watch next

Shareholder vote on Fortitude merger, November 19

Original filing on SEC EDGAR

More HeartSciences Inc. news

HeartSciences financing opens dilution before Fortitude merger vote | HSCS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.